Despite several CTLA-4 monoclonal antibody drugs have been recommended by the FDA for clinical trials in some cancers, they still face numerous challenges in terms of application such as complex structure, high immunogenicity, non-specifically binds to normal tissues and high production cost [31]. The gene discussed is CTLA4; the disease is cancer.